Minerva Neurosciences (NASDAQ:NERV) Now Covered by Analysts at StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV) in a report released on Sunday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright restated a “neutral” rating and set a $5.00 price objective on shares of Minerva Neurosciences in a report on Wednesday, November 6th.

Minerva Neurosciences Price Performance

Shares of NASDAQ:NERV opened at $2.28 on Friday. The business’s 50-day moving average is $2.26 and its 200 day moving average is $2.67. Minerva Neurosciences has a 1 year low of $2.06 and a 1 year high of $13.49. The firm has a market capitalization of $15.94 million, a P/E ratio of -5.18 and a beta of 0.11.

Minerva Neurosciences Company Profile

Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.